Ono Pharmaceutical Co., Ltd. (OPHLF)
USD 10.89
(0.0%)
USD 10.89
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 8.86 Billion JPY | -3.34% |
| 2023 | 9.16 Billion JPY | 4.16% |
| 2022 | 8.8 Billion JPY | -2.77% |
| 2021 | 9.05 Billion JPY | 8.28% |
| 2020 | 8.36 Billion JPY | 280.05% |
| 2019 | 2.2 Billion JPY | 208.99% |
| 2018 | 712 Million JPY | -26.22% |
| 2017 | 965 Million JPY | 14.47% |
| 2016 | 843 Million JPY | 39.57% |
| 2015 | 604 Million JPY | -38.11% |
| 2014 | 976 Million JPY | 315.32% |
| 2013 | 235 Million JPY | 1858.33% |
| 2012 | 12 Million JPY | -7.69% |
| 2011 | 13 Million JPY | -13.33% |
| 2010 | 15 Million JPY | -6.25% |
| 2009 | 16 Million JPY | -11.11% |
| 2008 | 18 Million JPY | -5.26% |
| 2007 | 19 Million JPY | -9.52% |
| 2006 | 21 Million JPY | -76.4% |
| 2005 | 89 Million JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 FY | 8.86 Billion JPY | -3.34% |
| 2024 Q2 | 8.97 Billion JPY | -4.4% |
| 2024 Q1 | 9.38 Billion JPY | 2.39% |
| 2024 Q3 | 8.58 Billion JPY | -4.32% |
| 2024 Q4 | 8.86 Billion JPY | 3.21% |
| 2023 FY | 9.16 Billion JPY | 4.16% |
| 2023 Q2 | 8.28 Billion JPY | -4.2% |
| 2023 Q1 | 8.64 Billion JPY | -1.74% |
| 2023 Q4 | 9.16 Billion JPY | 3.02% |
| 2023 Q3 | 8.89 Billion JPY | 7.4% |
| 2022 Q3 | 9.09 Billion JPY | 1.55% |
| 2022 FY | 8.8 Billion JPY | -2.77% |
| 2022 Q2 | 8.95 Billion JPY | 1.22% |
| 2022 Q4 | 8.8 Billion JPY | -3.24% |
| 2022 Q1 | 8.85 Billion JPY | -2.24% |
| 2021 Q4 | 9.05 Billion JPY | 0.04% |
| 2021 FY | 9.05 Billion JPY | 8.28% |
| 2021 Q1 | 7.88 Billion JPY | -5.65% |
| 2021 Q3 | 9.04 Billion JPY | -2.73% |
| 2021 Q2 | 9.3 Billion JPY | 17.92% |
| 2020 FY | 8.36 Billion JPY | 280.05% |
| 2020 Q1 | 8.37 Billion JPY | 280.55% |
| 2020 Q2 | 8.79 Billion JPY | 5.0% |
| 2020 Q3 | 8.89 Billion JPY | 1.18% |
| 2020 Q4 | 8.36 Billion JPY | -6.0% |
| 2019 Q4 | 2.2 Billion JPY | -2.53% |
| 2019 Q3 | 2.25 Billion JPY | 164.91% |
| 2019 Q2 | 852 Million JPY | 27.35% |
| 2019 Q1 | 669 Million JPY | -6.04% |
| 2019 FY | 2.2 Billion JPY | 208.99% |
| 2018 Q3 | 712 Million JPY | -10.44% |
| 2018 FY | 712 Million JPY | -26.22% |
| 2018 Q1 | 904 Million JPY | -6.32% |
| 2018 Q4 | 712 Million JPY | 0.0% |
| 2018 Q2 | 795 Million JPY | -12.06% |
| 2017 Q3 | 1.03 Billion JPY | 2.27% |
| 2017 FY | 965 Million JPY | 14.47% |
| 2017 Q4 | 965 Million JPY | -6.67% |
| 2017 Q2 | 1.01 Billion JPY | 13.85% |
| 2017 Q1 | 888 Million JPY | 5.34% |
| 2016 Q3 | 882 Million JPY | 16.67% |
| 2016 Q1 | 638 Million JPY | 5.63% |
| 2016 Q2 | 756 Million JPY | 18.5% |
| 2016 Q4 | 843 Million JPY | -4.42% |
| 2016 FY | 843 Million JPY | 39.57% |
| 2015 Q2 | 805 Million JPY | -9.04% |
| 2015 Q3 | 658 Million JPY | -18.26% |
| 2015 FY | 604 Million JPY | -38.11% |
| 2015 Q1 | 885 Million JPY | -9.32% |
| 2015 Q4 | 604 Million JPY | -8.21% |
| 2014 Q2 | 184 Million JPY | -12.38% |
| 2014 Q4 | 976 Million JPY | 542.11% |
| 2014 Q1 | 210 Million JPY | -10.64% |
| 2014 Q3 | 152 Million JPY | -17.39% |
| 2014 FY | 976 Million JPY | 315.32% |
| 2013 Q4 | 235 Million JPY | -9.96% |
| 2013 Q3 | 261 Million JPY | -8.74% |
| 2013 Q1 | 12 Million JPY | 0.0% |
| 2013 Q2 | 286 Million JPY | 2283.33% |
| 2013 FY | 235 Million JPY | 1858.33% |
| 2012 FY | 12 Million JPY | -7.69% |
| 2012 Q2 | 12 Million JPY | -7.69% |
| 2012 Q1 | 13 Million JPY | 0.0% |
| 2012 Q4 | 12 Million JPY | 0.0% |
| 2012 Q3 | 12 Million JPY | 0.0% |
| 2011 FY | 13 Million JPY | -13.33% |
| 2011 Q1 | 15 Million JPY | 0.0% |
| 2011 Q2 | 14 Million JPY | -6.67% |
| 2011 Q3 | 14 Million JPY | 0.0% |
| 2011 Q4 | 13 Million JPY | -7.14% |
| 2010 Q3 | 15 Million JPY | 0.0% |
| 2010 Q4 | 15 Million JPY | 0.0% |
| 2010 FY | 15 Million JPY | -6.25% |
| 2010 Q2 | 15 Million JPY | 0.0% |
| 2009 Q4 | 16 Million JPY | -5.88% |
| 2009 FY | 16 Million JPY | -11.11% |
| 2009 Q3 | 17 Million JPY | 0.0% |
| 2008 FY | 18 Million JPY | -5.26% |
| 2007 FY | 19 Million JPY | -9.52% |
| 2006 FY | 21 Million JPY | -76.4% |
| 2005 FY | 89 Million JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | 68.994% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 78.627% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -8793.485% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -20865.72% |
| Novartis AG | 26.34 Billion USD | 66.366% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -21832.514% |